CDXS - NASDAQ

Codexis, Inc.

Codexis, Inc.

CDXSยทNASDAQ

$2.69

+1.1%
HealthcareBiotechnology

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$244.51M
EPS-0.5000
P/E Ratio-3.23
Earnings Date08/12/2026
Codexis, Inc.

Codexis, Inc. Fair Value Envelope

CDXS ยท NASDAQ

Our analysis suggests that CDXS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.69, this represents a potential HIDDEN relative to our calculated worth for Codexis, Inc..

HIDDEN
Intrinsic Value
Current Price: $2.69

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$2.5B
+ Cash & Equivalents$50.8M
Firm Value-$2.4B
- Debt$73.2M
Equity Value-$2.5B
/ Shares Outstanding80,286,516B
DCF Value-$31
OVERVALUED BY 1262%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$30.1M
-$46.9M
-$73.0M
-$113.6M
-$176.8M
-$275.0M
-$428.0M
-$666.0M
-$1.0B
-$1.6B
Maintenance CapEx
-$1.4M
-$2.2M
-$3.4M
-$5.2M
-$8.2M
-$12.7M
-$19.8M
-$30.7M
-$47.8M
-$74.4M
Owner Earnings
-$31.5M
-$49.1M
-$76.4M
-$118.8M
-$184.9M
-$287.7M
-$447.7M
-$696.7M
-$1.1B
-$1.7B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$29.2M
-$42.1M
-$60.6M
-$87.3M
-$125.8M
-$181.3M
-$261.2M
-$376.4M
-$542.3M
-$781.3M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your CDXS research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.